Clene (CLNN) Stock Price, News & Analysis

Company Overview

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS). Early-stage studies have explored safety, tolerability, and preliminary signals of biological activity, while ongoing Phase 2 trials aim to evaluate efficacy endpoints in patient populations. The company has also initiated trials in spinal cord injury to investigate broader applications of its nanoparticle technology in central nervous system repair and protection.

Headquartered in Salt Lake City, Utah, Clene maintains research and development operations in the United States and collaborates with academic institutions and clinical sites across North America and Australia. These partnerships support its translational research efforts and enable access to patient cohorts for clinical investigation. Clene has secured manufacturing capabilities for its nanoparticle formulations and is working to scale production processes in anticipation of later-stage clinical studies and potential commercialization.

Clene is led by a management team with experience in biotechnology development, neuroscience research, and clinical operations. The company continues to expand its leadership bench through strategic hires and external collaborations, with the goal of advancing its pipeline of nanoparticle therapeutics toward regulatory approval and broader patient access.

Key Stats

• Today's Range: $6.24 to $6.46
• 50-Day Range: $5.33 to $7.39
• 52-Week Range: $3.25 to $13.50
• Volume: 12,410 shs
• Average Volume: 283,447 shs
• Market Capitalization: $82.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.25
• Consensus Rating: Moderate Buy

Clene Stock Analysis - MarketRank™

Clene scored higher than 77% of companies evaluated by MarketBeat, and ranked 145th out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Clene has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Clene has a consensus price target of $33.25, representing about 420.3% upside from its current price of $6.39.

Amount of Analyst Coverage

Clene has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Clene are expected to grow in the coming year, from ($1.58) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Clene is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Clene is -2.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.79% of the float of Clene has been sold short.

Short Interest Ratio / Days to Cover

Clene has a short interest ratio ("days to cover") of 9.73.

Change versus previous month

Short interest in Clene has recently decreased by 6.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Clene does not currently pay a dividend.

Dividend Growth

Clene does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.89

News Sentiment

Clene has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Clene this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for CLNN on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

4 people have added Clene to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Clene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,902,330.00 in company stock.

Percentage Held by Insiders

28.30% of the stock of Clene is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

23.28% of the stock of Clene is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 7/14/2026
• Next Earnings (Estimated): 8/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLNN
• CIK: 1822791
• Web: clene.com
• Phone: 801-676-9695
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Clene: $33.25
• High Price Target: $48.00
• Low Price Target: $23.00
• Potential Upside/Downside: +417.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.17 million
• Net Margins: -25,009.70%
• Pretax Margin: -25,009.70%
• Return on Equity: N/A
• Return on Assets: -137.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.94
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $200 thousand
• Price / Sales: 410.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.62) per share
• Price / Book: -3.97

Miscellaneous

• Outstanding Shares: 12,780,000
• Free Float: 9,162,000
• Market Cap: $82.12 million
• Optionable: No Data
• Beta: 0.92